Investment Firm Nxt2b to Buy 49 Percent of Olink Bioscience | GenomeWeb

By Adam Bonislawski

Investment firm Nxt2b has signed an agreement to purchase 49 percent of all outstanding shares of Olink Bioscience for an undisclosed amount.

According to Olle Kämpe, a scientific advisor at Nxt2b and a professor of molecular medicine at Uppsala University, the firm sees great potential in packaging Olink's proximity ligation technology in ready-to-use formats for scientific, pharmaceutical, and clinical researchers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.